Recombinant Human IL-18/IL-1F4 Biotinylated Protein, CF

Name: Recombinant Human IL-18/IL-1F4 Biotinylated Protein, CF
Brand: R&D Systems
SKU: BT9124
Price: 454 USD
Availability: InStock

R&D Systems | Catalog # BT9124

Submit a review

Product Documents

Biotinylated

100% Guarantee

Product Specifications
Scientific Data
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems E. coli-derived Recombinant Human IL-18/IL-1F4 Biotinylated Protein (BT9124)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

E. coli

Accession Number

Q14116

Structure / Form

Biotinylated via amines

Conjugate

Biotin

Applications

Bioactivity

View all IL-18/IL-1F4 Proteins and Enzymes »

Product Specifications

Source

E. coli-derived human IL-18/IL-1F4 protein
Tyr37-Asp193

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Tyr37

Predicted Molecular Mass

18 kDa

SDS-PAGE

15-21 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human IL-18 BPa His-tag Protein (Catalog # 11236-BP) is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human IL‑18/IL‑1F4 (Catalog # BT9124) that produces 50% of the binding response is 1.50-12.0 ng/mL.

Scientific Data Images for Recombinant Human IL-18/IL-1F4 Biotinylated Protein, CF

Biotinylated Recombinant Human IL-18/IL-1F4 Protein Binding Activity.

Measured by its binding ability in a functional ELISA. When Recombinant Human IL-18 BPa His-tag Protein (11236-BP) is immobilized at 0.25 μg/mL (100 μL/well), the concentration of Biotinylated Recombinant Human IL-18/IL-1F4 (Catalog # BT9124) that produces 50% of the binding response is 1.50-12.0 ng/mL.

Biotinylated Recombinant Human IL-18/IL-1F4 Protein SDS-PAGE.

2 μg/lane of Biotinylated Recombinant Human IL-18/IL-1F4 Protein (Catalog # BT9124) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 15-21 kDa.

Formulation, Preparation, and Storage

BT9124

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS and DTT with Trehalose.
Reconstitution	Reconstitute at 250 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: IL-18/IL-1F4

Interleukin-18 (IL-18) is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes, gamma delta T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases. IL‑18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation (1-3). IL-18 binds to the widely expressed IL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex (4, 5). Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs (6). In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN-gamma production and the cytolytic activity of CD8+ T cells and NK cells (7, 8). In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4+ T cells and basophils (9, 10). In the presence of IL-1 beta or IL-23, IL-18 induces the antigen-independent production of IL-17 by gamma delta T cells and CD4+ T cells (11). IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst (12, 13). In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis (14). Mature human IL-18 shares approximately 63% amino acid sequence identity with mouse and rat IL-18 (15). Alternative splicing in human ovarian cancer generates an isoform that is resistant to Caspase-1 activation (16). A cell surface form can be expressed on M-CSF induced macrophages and released in response to bacterial endotoxin (17).